



A REVIEW: AZADIRACHTA INDICA AS ANTIHYPERLIPIDEMIC ACTIVITY

* Shalu Baghel¹, Charanjeet Singh²

¹Department of Pharmacology, Jaipur College of Pharmacy, Jaipur, Rajasthan, India

²Principal, Biyani Institute of Pharmaceutical Sciences, Champapura, Jaipur, Rajasthan, India

Article Info: Received 10 September 2019; Accepted 14 November. 2019

DOI: <https://doi.org/10.32553/jbpr.v8i6.677>

Address for Correspondence: Shalu Baghel

Conflict of interest statement: No conflict of interest

ABSTRACT:

Antihyperlipidemic agents having various pharmacological actions are being tested clinically³. Elevated lipid levels result from increased absorption through the gut or enhanced endogenous synthesis and therefore two ways are feasible to reduce hyperlipidemia; to block endogenous synthesis or to decrease absorption. Whole plant of *Azadirachta indica* gives the Antihyperlipidemic activity. Several genetic conditions are known to responsible for primary Hyperlipidemia, such as lipoprotein lipase deficiency, apolipoprotein C-II deficiency etc. In our study we choose cholesterol diet which contains the common ingredients in our daily food. Cholesterol feeding has been often used to elevate serum or tissue cholesterol levels to assess the hypercholesterolemia- related metabolic disturbances in animals. Cholesterol feeding alone however does not affect the serum TG level.

Keywords: *Azadirachta indica*, antihyperlipidemic, antiatherosclerotic activities, Maceration.

1. INTRODUCTION:

Hyperlipidemia is a secondary metabolic dysregulation associated with diabetes. Besides the cause effect relationship with diabetes, elevated serum level of triglycerides, cholesterol and LDL are major risk factors for the premature development of cardiovascular disease like atherosclerosis, hypertension, coronary heart disease etc¹. Increased plasma lipid levels mainly total cholesterol, triglycerides and LDL along with decrease in HDL are known to cause hyperlipidemia which is the reason for initiation and progression of atherosclerosis impasse².

Antihyperlipidemic agents having various pharmacological actions are being tested clinically³. Elevated lipid levels result from increased absorption through the gut or enhanced endogenous synthesis and therefore two ways are feasible to reduce hyperlipidemia; to block endogenous synthesis or to decrease absorption. Both factors can be evaluated in normal animals without artificial diets.

Salacia chinensis (Family:Hippocrateaceae) is a woody climbing plant found in the submontane

forests in Sri Lanka and India. The roots and stems of this plant have been extensively used in the treatment of diabetes in the ayurvedic system of Indian traditional medicine. Furthermore, other plant species of the *Salacia* genus (e.g., *S. prinoidea*, *S. reticulata*) have been historically used in ayurvedic medicine for their antidiabetic properties³. *Salacia chinensis* have been used in India and in other countries as a tonic, blood purifier and to treat amenorrhea and dysmenorrhea⁴. Its root bark is used in treatment of gonorrhoea, rheumatism and skin diseases. Its aqueous extract showed significant hypoglycemic activity. Root bark boiled in oil or as decoction or as powder is used for the treatment of rheumatism, gonorrhoea, itches, asthma, thirst and ear diseases⁵.

Patients with Diabetes mellitus DM are at significantly increased risk of CHD compared with non diabetic patients of similar age. DM patients without known CHD appear to have a risk for first myocardial infarction (MI) similar to the risk for recurrent MI of non-DM patients with CHD and a prior coronary event. Patients with type 2 diabetes commonly have other risk factors (hypertension,

high LDL-C, low HDL-C, obesity) that increase risk for cardiac events .

High lipid levels can speed up a process called atherosclerosis, or hardening of the arteries. From inside, arteries are normally smooth and unobstructed , but as increase in age, a sticky substance called plaque forms in the walls of arteries, which is made of lipids and other materials circulating in blood.

As more plaque builds up, arteries can narrow and stiffen. Eventually, enough plaque may build up to reduce blood flow through arteries




Figure 1:

Hyperlipidemia is typically asymptomatic and is frequently detected during routine screening. Hyperlipidemia often results from delayed or defective clearance, or overproduction of VLDL by the liver, which is subsequently transformed into LDL. Hypercholesterolemia involves defective hepatic and nonhepatic LDL receptors. Excess intake of saturated fats increases the liver's production of VLDL and triglycerides via a molecular mechanism involving protein activators. Saturated fats are found in animal products, such as meat, whole milk dairy products (milk, cream, cheese), and butter, and tropical oils (palm, palm kernel, and coconut).

High concentrations of total and LDL cholesterol and low levels of high-density lipoprotein (HDL) cholesterol, predicts cardiovascular risk in both men and women. High triglyceride levels have been associated with greater risk in women only. The risk of cardiovascular disease increases by an average of 2%, for each corresponding 1% rise in

total cholesterol. Adolescents with high TC or LDL may have a genetic disorder of lipid metabolism such as familial hypercholesterolemia or familial combined hypercholesterolemia. Those with homozygous forms of these disorders can experience myocardial infarction or other events during childhood or early adolescence. Familial hypercholesterolemia is often diagnosed in adolescence and is characterized by high LDL levels that can be refractory to dietary treatment. These patients can present clinically with xanthomas or xanthelasma— cholesterol deposits under the skin on the hands, elbows, knees, heel or eyelids

2. TYPES OF HYPERLIPIDEMIA:

Depending on the complexity of the disease, Hyperlipidemia classified into two types.

- a . Primary Hyperlipidemia.
- b. Secondary / Acquired Hyperlipidemia.

2.1 Primary Hyperlipidemia:

Several genetic conditions are known to responsible for primary Hyperlipidemia, such as lipoprotein lipase deficiency, apolipoprotein C-II deficiency etc. The primary hyperlipidemia may be treated by anti-lipidemic drugs. Primary Hyperlipidemia are again classified into 5 types.

- Type-I Hyperlipidemia: Severe elevation of chylomicrons (CMs) with resultant elevation of TGs.
- Type-II (A) Hyperlipidemia: Elevations of LDL – C only.
- Type-II (B) Hyperlipidemia: Elevations of both LDL-C and triglycerides (TG's).
- Type-III Hyperlipidemia: It develops due to defect in VLDL remnant Clearance.
- Type-IV Hyperlipidemia: It is characterized by hyper TG's
- Type-V Hyperlipidemia: Characterized by elevated levels of CMs and VLDL.

2.2 Secondary Hyperlipidemia

In this many factors can influence the level of TGs in circulation like diabetes, obesity etc. Secondary Hyperlipidemia demands treatment of original diseases rather than Hyperlipidemia.

3. CAUSES OF SECONDARY HYPERLIPIDEMIA:

- Metabolic influences: Diabetes, obesity, hyperuricemia, glycogen storage diseases.
- Harmonal influences: Insulin, estrogen, thyroxine
- Nutritional influences:-Alcohol, high carbohydrate intake

- Disease states:-Renal diseases, renal failure, nephrotic syndrome
- Drugs: - Diuretics
Beta-blockers
Glucocorticoids
Estrogen replacement

4. CONCLUSION:

It has been well established that nutrition plays an important role in the etiology of hyperlipidemia and atherosclerosis. In our study we choose cholesterol diet which contains the common ingredients in our daily food. Cholesterol feeding has been often used to elevate serum or tissue cholesterol levels to assess the hypercholesterolemia-related metabolic disturbances in animals. Cholesterol feeding alone however does not affect the serum TG level. It is assumed that a high level of saturated fat in addition to cholesterol is required to significantly elevate serum TG level in rat model.

Development of atherosclerotic disease is a complicated process involving accumulation of lipid-containing particles in the walls of coronary arteries other major arteries in the body. Similarly the present study there was a significant weight gain in cholesterol control (toxic), as compared to normal control groups. Treatment with *A. Indica* Leaves extracts significantly reduced the weight gain Lowering high cholesterol levels significantly reduce the risk of heart attacks, strokes, and death. A rise in the LDL may cause deposition of cholesterol in arteries and aorta and it is a direct risk factor for CHD.

REFERENCES:

1. Nomura H, Kimura Y, Okamoto O, Shiraishi G. Effects of antihyperlipidemic drugs and diet plus exercise therapy in the treatment of patients with moderate Hypercholesterolemia. *Clin Ther.* 1996;18:196.
2. Inman WD, Reed MJ. In-ventors; Shaman Pharmaceuticals, assignee Triterpenoid compound for the treatment of diabetes. US Patent 5, 691, 386. 1997 Nov 25;
3. Gopalakrishnan S, Ismail ST, Begum HV, Elango V. Anti-inflammatory activity of *Salaciaoblona* Wall. And *Azimatetracantha* Lam. *J Ethnopharmacol.* 1997;56:145–52.
4. Naveen A. Hepatoprotective activity of ethanolic extract of root bark of *Salaciachinensis*. *J Pharm Res.* 2010;3:833–4.
5. PeriyarSellamuthu, Muniappan BP, Perumal SM, Kandasamy M. Antihyperglycemic effect of mangiferin in streptozotocin induced diabetic rats. *J Health Sci.* 2009;55:206–14.
6. Yoshikawa M, Zhang Y, Wang T, Nakamura S, Matsuda H. New triterpene constituents, foliasalacins A₁-A₄, B₁-B₃, and C, from the leaves of *Salaciachinensis*. *Chem Pharm Bull (Tokyo)* 2008;56:915–20.
7. Jansakul C, Jusapalo N, Mahattanadul S. Hypotensive effect of n-butanol extract from stem of *Salaciachinensis* in rats, ISHS Acta Horticulturae 678: III WOCMAP Congress on Medicinal and Aromatic Plants. Targeted Screening of Medicinal and Aromatic Plants, Economics and Law. Vol. 4
8. Ministry of Health (India) (948). *Pharmacopoeia of India*. Government of India. 1982:650.
9. Khandewal KR. 14th ed. Pune, India: NiraliPrakashan; 2005. *Practical Pharmacognosy*; pp. 146–57.
10. Vinay Kumar, Abul K Abbas and Nelson F. *Pathology: basis of disease*. 7th Edn. New Delhi: Elsevier; 2002:46-49.
11. Brendan J Coughlan and Matthew J Sorrentino. Does hypertriglyceridemia increase risk for CAD. *Post graduate medicine, the practical peer-reviewed; J for Prim Care Phys.* 2000; 108(7):56.
12. <https://online.epocrates.com/u/2924170/Hypercholesterolemia/Basics/Etiology>.
13. William Winter and Desmond Schatz. Pediatric lipid disorders in clinical practice. *Medicine Specialties>Pediatrics>Cardiology*. Available from URL: file:///C:/Documents%20and%20Settings/Administrator/Desktop/eti ology.html_
14. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risk by levels and ratio. *Ann Inter Med.* 1994;121:641- 647.
15. Fungwe TV, Cagen LM, Cook GA, et al. Dietary cholesterol stimulates hepatic biosynthesis of triglyceride and reduces oxidation of fatty acids in the rat. *J Lipid Res.* 1993; 34: 933 – 941.
16. Inadera H, Shirai K and Saito Y. The enzymes related to lipoprotein metabolism (Hmg-coareductase, 7-alpha hydroxylase). *Japanese J of Clinical Medicine.* 1990; 48(11): 2483-91.
17. American heart association. Lipoproteins. Available from URL: <http://www.americanheart.org/presenter.jhtml?identifier=4600>.